So should Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable co ...

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The ...

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

Good morning, and welcome to Y-mAbs Therapeutics First Quarter 2025 Earnings ... institutions that have historically not been users of YmAb’s differentiated anti-GD2 therapy.

YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is ...

Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note published on Monday morning,RTT News reports. The brokerage currently ...

Y-mAbs Therapeutics Inc (NASDAQ:YMAB) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is $27.29 million, and the earnings are expected to come in ...

The market expects Y-mAbs Therapeutics, Inc. (YMAB) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024.

Y-mAbs Therapeutics, Inc. (YMAB) has been on a downward spiral lately with significant selling pressure. After declining 25.7% over the past four weeks, the stock looks well positioned for a trend ...

Y-mAbs Therapeutics, Inc. (YMAB) has been on a downward spiral lately with significant selling pressure. After declining 26.9% over the past four weeks, the stock looks well positioned for a trend ...